Filing Flows › Comparisons › JANX vs GOSS
Janux Therapeutics vs Gossamer Bio: JANX and GOSS compared
Janux Therapeutics is the larger company: $9.3M of revenue in its latest quarter (Q3 2026) against $9.2M for Gossamer Bio (Q2 2026). Janux Therapeutics is growing faster (-7% against -20% a year earlier). Gossamer Bio is more profitable, with an operating margin of -282.2% against -336.5%.
Where the money goes: JANX and GOSS
Janux Therapeutics (JANX) · Q3 2026
Janux Therapeutics, Q3 2026: revenue $9.3M (-7% year over year), operating margin -336.5%, net loss $21.6M, operating cash flow −$25.2M. The chart follows the revenue to costs, profit and cash.
Gossamer Bio (GOSS) · Q2 2026
Gossamer Bio, Q2 2026: revenue $9.2M (-20% year over year), operating margin -282.2%, net earnings $16.9M, operating cash flow −$39.4M. The chart follows the revenue to costs, profit and cash.
| Janux Therapeutics (JANX) | Gossamer Bio (GOSS) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q2 2026 |
| Revenue | $9.3M | $9.2M |
| Revenue growth, Y/Y | -7% | -20% |
| Operating margin | -336.5% | -282.2% |
| Net earnings | −$21.6M | $16.9M |
| Net margin | -232.2% | 182.9% |
| Operating cash flow | −$25.2M | −$39.4M |
| Market value | $1.2B | — |
| Analysts’ mean target | $32.53 | — |
Questions
Which is bigger, Janux Therapeutics or Gossamer Bio?
Janux Therapeutics is the larger company: $9.3M of revenue in its latest quarter (Q3 2026) against $9.2M for Gossamer Bio (Q2 2026).
Is Janux Therapeutics or Gossamer Bio growing faster?
Janux Therapeutics is growing faster (-7% against -20% a year earlier).
Which is more profitable, Janux Therapeutics or Gossamer Bio?
Gossamer Bio is more profitable, with an operating margin of -282.2% against -336.5%.
More: Janux Therapeutics earnings · how Janux Therapeutics makes money · Gossamer Bio earnings · how Gossamer Bio makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 5, 2026; 10-Q filed Aug 13, 2026). Fiscal quarters can end on different dates. Not investment advice.